Category: Vascular
Vascular
Covidien wins FDA clearance for its Solitaire FR revascularization device, intended to restore blood flow to the brain by removing clots from blocked vessels.
Covidien plc (NYSE:COV) won FDA clearance for its Solitaire FR revascularization device for removing blood clots and restoring blood flow in the brains of patients suffering acute ischemic stroke.
The federal watchdog agency cleared the device, which physically removes blood clots from vessels, on the basis of data gathered during Covidien's Swift study, the first of its kind to compare mechanical interventions for acute ischemic stroke, according to a press release.
A federal court finds that W.L. Gore was not a co-inventor of vascular grafts patented by C.R. Bard, affirming a lower court's $371 million decision in favor of Bard. Analysts weigh in and Wall Street gives Bard some love.
Updated Feb. 10, 2012, at 1:30 p.m. with share values and analysts' reactions.
A U.S. federal judge this week upheld C.R. Bard's (NYSE:BCR) win against W.L. Gore & Associates over vascular graft patents.
A federal court finds that W.L. Gore was not a co-inventor of vascular grafts patented by C.R. Bard, affirming a lower court's $371 million decision in favor of Bard.
A U.S. federal judge this week upheld C.R. Bard's (NYSE:BCR) win against W.L. Gore & Associates over vascular graft patents.
The court affirmed Bard's $371 million win from a 2007 decision when an Arizona jury found that Gore willfully infringed on patents for vascular tubing.
AngioDynamics agrees to pay $14.20 per share, or about $372 million, for vascular device maker Navilyst Medical.
Updated February 1, 2012, at 6:30 p.m.
AngioDynamics (NSDQ:ANGO) agreed to pay roughly $372 million for Navilyst Medical, the vascular device business spun out by Boston Scientific (NYSE:BSX) in 2008 to Avista Capital Partners.
St. Jude responds to a summit on the recall of its Riata defibrillator leads, Boston Scientific fights the hype on deformation concerns on its thinner stents and Covidien announces a new head for its $1.4 billion global vascular therapies business.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you're still in the know with MassDevice +3.
Abbott initiates a clinical trial to study its Esprit drug eluting vascular scaffold for the treatment of pain associated with peripheral artery disease.
Abbott (NYSE:ABT) launched a European clinical trial for its Esprit drug-eluting bioresorbable vascular scaffold to treat leg pain associated with peripheral artery disease.
The Esprit drug eluting BVS is designed to treat blockages in the superficial femoral arteries and iliac arteries that cause leg pain in patients while walking.
Concerns about broken vena cava filters resurface as a Japanese study finds a high rate of fracture for Cordis Corp.'s TrapEase permanent implant.
TrapEase permanent vena cava filter
A new study reported a high fracture rate among permanent inferior vena cava filters made by Cordis Corp., a device-making arm of Johnson & Johnson (NYSE:JNJ).
In a Japanese study of 20 patients with Cordis' TrapEase IVC filter, the devices fractured in half the patients at 50 months.
